ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "IL-6"

  • Abstract Number: 436 • 2013 ACR/ARHP Annual Meeting

    Efficacy and Safety Study Of a Sequential Therapy Of Tocilizumab and, If Initially Inadequately Responded To Tocilizumab, Followed By Rituximab In Patients With Rheumatoid Arthritis and Inadequate Response To Traditional Disease Modifying Anti-Rheumatic Drugs (MIRAI)-Interim Analysis 2

    Thomas Doerner1, Hans Peter Tony2, Hendrik Schulze-Koops3, Jörg Kaufmann4, Peter Kaestner5, Herbert Kellner6, Reiner Kurthen7, S. Wagner8, Marvin A. Peters9 and Christof Iking-Konert10, 1Dept Int Med (Charite), Humdoldt Univ, Berlin, Germany, 2Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, 3Division of Rheumatology, University of Munich, Munich, Germany, 4Ambulant Centres for Rheumatology, Rheumatologist, Ludwigsfelde, Germany, 5Outpatient Department of Rheumatology, Ambulantes Rheumazentrum Erfurt, Germany,, Erfurt, Germany, 6Centre for Inflammatory Joint Diseases, Munich, Germany, 7Rheumapraxis, Aachen, Germany, 8Internistische Schwerpunktpraxis für Rheumatologie, Halle, Germany, 9Roche Pharma AG, Grenzach-Wyhlen, Germany, 10Department of Rheumatology, University Hospital Hamburg Eppendorf, Hamburg, Germany

    Background/Purpose: The MIRAI study evaluates a sequential exposure to two defined biologics under rigorous study conditions within a homogeneous population of patients (pts) who inadequately…
  • Abstract Number: 1855 • 2013 ACR/ARHP Annual Meeting

    IL-6 Promotes Systemic Bone Loss Via Upregulation Of S1PR2 In Osteoclast Precursors In a Mouse Collagen-Induced Arthritis Model

    Keisuke Tanaka, Misato Hashizume, Hiroto Yoshida, Miho Suzuki and Yoshihiro Matsumoto, Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan

    Background/Purpose: Systemic bone loss is a hallmark of rheumatoid arthritis (RA). Inflammatory cytokines such as interleukin-6 (IL-6) promote bone resorption by osteoclasts. Recent studies have…
  • Abstract Number: 1866 • 2013 ACR/ARHP Annual Meeting

    Primary Human Cell BioMAP® Profiling Of Methotrexate, Tocilizumab, Adalimumab, and Tofacitinib Reveals Different Mechanisms Of Action With Distinct Phenotypic Signatures

    Seng-Lai Tan1, Alison O'Mahony2, Ellen L. Berg2, Kandeepan Ganeshalingam3 and Ernest H. Choy4, 1Inflammation, Hoffmann-La Roche, Nutley, NJ, 2BioSeek, South San Francisco, CA, 3F. Hoffmann-La Roche, Basel, Switzerland, 4Cardiff University School of Medicine, Cardiff, United Kingdom

    Background/Purpose: Proinflammatory cytokines cause joint inflammation and destruction in patients with rheumatoid arthritis, as exemplified by the therapeutic success of inhibiting tumor necrosis factor alpha…
  • Abstract Number: 1833 • 2013 ACR/ARHP Annual Meeting

    Combination Of TNF and IL-6 Induces Osteoclast-Like Cells With Bone-Resorption Activity Both In Vitro and In Vivo

    Kazuhiro Yokota, Kojiro Sato and Toshihide Mimura, Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan

    Background/Purpose: Although TNF inhibitors suppress bone destruction in patients with rheumatoid arthritis (RA), TNFα stimulation alone does not directly induce osteoclasts, bone-resorbing cells. With the…
  • Abstract Number: 1823 • 2013 ACR/ARHP Annual Meeting

    IL-6 Suppresses Osteoblast Differentiation Through The SHP2/MEK2 and SHP2/Akt2 Pathways In Vitro

    Shoichi Kaneshiro1, Kosuke Ebina1, Kenrin Shi1, Chikahisa Higuchi2, Hideki Yoshikawa1, Jun Hashimoto3 and Makoto Hirao4, 1Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan, 2Osaka University Graduate School of Medicine, Suita, Japan, 3Dept of Rheumatology, Osaka-Minami Medical Center, Kawachinagano City, Japan, 4Orthopaedic Surgery, Osaka Minami Medical Center, Osaka, Japan

    Background/Purpose: Interleukin-6 (IL-6), a potent inflammatory cytokine, plays a key role in the pathogenesis of rheumatoid arthritis (RA), including osteoporosis not only in inflamed joints…
  • Abstract Number: 1601 • 2013 ACR/ARHP Annual Meeting

    The Presence Of IgG-Immune Complexes In The Cerebrospinal Fluids Is Associated With Central Neurocychiatric Manifestatin But Not With Intrathecal Production Of Proimmflammatory Cytokines/Chemokines Such as  Interferon-α In Systemic Lupus Erythematosus

    Taku Yoshio1, Hiroshi Okamoto2, Kazuhiro Kurasawa3, Yoshiaki Dei4, Shunsei Hirohata5 and Seiji Minota6, 1Division of Rheumatology and Clinical Immunology, Jichi Medical University, School of Medicine, Shimotsuke-shi, Tochigi-ken, Japan, 2Minami-Otsuka Institute of Thechnology, Minami-Otsuka Clinic, Tokyo, Japan, 3Clinical Immunology, Dokkyo Medical University, Mibu-machi, Shimotsuga-gun, Tochigi-ken, Japan, 4Saiseikai Utsunomiya Hospital, Utsunomiya-shi, Tochigi-ken, Japan, 5Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, 6Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke,Tochigi, Japan

    Background/Purpose:  IgG-Immune complexes (IC) formed by CSF autoantibodies in patients with neuropsychiatric syndromes of systemic lupus erythematosus (NPSLE) has reported to stimulate the production of…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology